Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 31;57(1):20-28.
doi: 10.5045/br.2022.2022043.

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park  1 , Dae-Young Kim  2 , Seongkoo Kim  3 , Young Bae Choi  4 , Dong-Yeop Shin  5 , Jin Seok Kim  6 , Won Sik Lee  7 , Yeung-Chul Mun  1 , Jun Ho Jang  8 , Jong Wook Lee  9 , Hoon Kook  10 , On Behalf Of Korean Aplastic Anemia Working Party
Affiliations
Review

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park et al. Blood Res. .

Abstract

Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.

Keywords: Immune thrombocytopenia; Management; Recommendation.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Algorithm for the selection of second-line therapy in adult patients with ITP.
See this image and copyright information in PMC

References

    1. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83:83–9. doi: 10.1111/j.1600-0609.2009.01247.x. - DOI - PubMed
    1. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145:235–44. doi: 10.1111/j.1365-2141.2009.07615.x. - DOI - PubMed
    1. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377–83. doi: 10.1111/j.1538-7836.2006.02147.x. - DOI - PubMed
    1. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–80. doi: 10.1002/ajh.21616. - DOI - PubMed
    1. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149:855–64. doi: 10.1111/j.1365-2141.2010.08176.x. - DOI - PubMed